351eP Exploring influential factors for pCR after neoadjuvant therapy for triple-negative breast cancer - in COVID and non-COVID patients

Results: Fifty-two patients (28.9%) developed endometrial pathology.The mean age was 54.3 years, with the majority being premenopausal (72%).Most patients had no prior gynecological history and no use of hormonal contraception.The main comorbidities were obesity (24%) and diabetes (4%).Clinically, abnormal uterine bleeding was the most common symptom (18%), followed by pelvic pain (7%).Pelvic ultrasound showed endometrial thickening in 54% of cases, with half presenting an endometrial thickness between 8 and 14 mm.Hysteroscopy was performed in 47% of patients, confirming histological diagnoses predominantly consisting of endometrial polyps (21%), hyperplasia (17%), and fibroids (39%).No cases of endometrial cancer were observed in this cohort, despite a mean duration of tamoxifen exposure of 58 months.Additionally, 39% of patients were subsequently switched to aromatase inhibitor therapy.The one-year disease-free survival rate was 91%, reflecting good disease control in this population. Conclusions:Tamoxifen is associated with a high prevalence of benign endometrial pathology.The absence of endometrial cancer in our cohort is a reassuring finding.Gynecological follow-up remains non-systematic.These findings highlight the importance of tailored surveillance in high-risk patients, particularly those with obesity.